Bispecific antibodies engage T cells for antitumor immunotherapy. - Wikidata - wikimedia - TriplyDB

Bispecific antibodies engage T cells for antitumor immunotherapy.

Bispecific antibodies engage T cells for antitumor immunotherapy.

http://www.wikidata.org/entity/Q34174334

about

Immunotherapy advances for glioblastoma Novel immunotherapies for hematologic malignancies Are BiTEs the "missing link" in cancer therapy?Mechanisms of action of therapeutic antibodies for cancer The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk The development of bispecific antibodies and their applications in tumor immune escape.An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting.Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma.ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy.T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.Fab-based bispecific antibody formats with robust biophysical properties and biological activity Chemically programmed bispecific antibodies that recruit and activate T cells Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done.Cytokine-induced killer cells promote antitumor immunity A novel bispecific antibody recruits T cells to eradicate tumors in the "immunologically privileged" central nervous system.Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.Recent advances in the application of antibodies as therapeutics.Monoclonal antibodies in oncology therapeutics: present and future indications.Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.Arming oncolytic viruses to leverage antitumor immunity.Giving oncolytic vaccinia virus more BiTE.Cancer testis antigen and immunotherapy.Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody Tumor-associated antigens for specific immunotherapy of prostate cancer T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.Harnessing the immune system in the battle against breast cancer.Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity.

P2860

Q26866513-276EEA6C-E04F-47E8-945C-EB646BCD6ED1 Q27004436-A745E492-9224-4090-86F8-2134D4D9D6EA Q28083907-E71E633B-152D-43B1-9D1C-23AE2272241D Q28385366-ACE32369-756F-4230-B6A9-F0E4603A1EA7 Q28547458-1EC6D972-3B70-4A8E-B331-9E7863A20E34 Q33630292-D4BC19D7-D186-49C7-9235-D87570A00AF1 Q33665884-0A30B315-69DF-4E3B-AC7A-77C866218690 Q34246195-4861247F-5433-4BF8-9992-71C1656E5F0A Q35005791-E647CE51-6D5C-4153-AE79-5C3681B13FBE Q35033324-1756A178-D532-4F4A-82BB-892BFE3BFA80 Q35674158-F295AA7F-DF82-4213-B375-20C4B822D2EC Q35971763-450C4132-3EB8-474C-99E5-98B7007FEBA9 Q36022539-103B093B-0A17-4FEF-BC85-E9CFC9023268 Q36213193-BC02903B-A7C3-404C-B234-576FC3A5FD30 Q36217175-E9007602-EAB8-4F7B-8BF7-E9E6BD600A2F Q36512160-CF1D7DCB-AB06-437C-901B-93E8A78E24D4 Q36600044-E00D8F7A-1664-4E49-9C40-F0F177F8AAC5 Q36741617-5FDF5B4D-5062-413C-AB8C-D517B837CA75 Q36845815-F8BF168E-29DE-4AC6-981C-B72E225873F2 Q37102753-65A4ABA5-FF5A-4500-9AA5-8248BCA67141 Q37457329-7007C5CE-56B9-4B9A-A8E0-2236348E61A2 Q37512086-5F8718E7-413A-4CFF-89E4-D0387D595F43 Q37598166-60379BBB-9A97-43DA-9801-B86010B701C4 Q37698921-0CB28725-DADA-486E-8782-A4BE19CB55F7 Q37968255-08948A68-5ADB-43A0-A6D5-5AF362E75446 Q38071374-BB5E1620-E564-4BC0-B22A-2B68574C5D86 Q38074885-663769F4-CFF9-4227-8A72-20180DBB4091 Q38470166-8D8C7055-DEBE-441D-94B0-B82119F3E674 Q38648659-6C5C8003-EA7B-45D6-9149-44EDF02774DE Q38912232-D03C5274-9814-4021-803F-30EA5576F245 Q39323781-E2B1DAB4-FA0F-4B84-BBF9-7F0AFB7816DD Q41590699-33D775F4-E47A-4677-9155-EA743118E941 Q41871348-4408EBE4-14CE-4BCD-9831-C18C4F054A7D Q41977894-28802729-367D-4CCC-ABF9-DC0971025719 Q44139242-04E20E81-2727-419B-920C-A98705EDAB94 Q49884762-DF32427D-372C-4809-BC82-D8A01B787556 Q53063068-30896CA7-A622-4353-A3F2-6EE43185699E Q54325947-518FD786-BCCD-48E0-9204-D9327BF6C7A3

P2860

Bispecific antibodies engage T cells for antitumor immunotherapy.

http://www.wikidata.org/entity/Q34174334

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Bispecific antibodies engage T cells for antitumor immunotherapy.

@ast

Bispecific antibodies engage T cells for antitumor immunotherapy.

@en

Bispecific antibodies engage T cells for antitumor immunotherapy.

@nl

type

label

Bispecific antibodies engage T cells for antitumor immunotherapy.

@ast

Bispecific antibodies engage T cells for antitumor immunotherapy.

@en

Bispecific antibodies engage T cells for antitumor immunotherapy.

@nl

prefLabel

Bispecific antibodies engage T cells for antitumor immunotherapy.

@ast

Bispecific antibodies engage T cells for antitumor immunotherapy.

@en

Bispecific antibodies engage T cells for antitumor immunotherapy.

@nl

P1433

Q34174334-EF46E04C-5C7F-4F17-A3B8-D4696DA63817

P1476

Q34174334-38064B8F-DDAE-4D8E-A874-8B972234CD36

P2093

Q34174334-281357EA-7DE7-45F7-9563-7896892422FA

Q34174334-6879232A-F814-4614-B13C-B39FB86FB6E2

Q34174334-A8E5BBE3-FC77-498D-9D11-474EEB6320A1

Q34174334-EC6505B9-2D38-46BD-AE69-31A51EDD994E

Q34174334-FC7516A0-9F45-4A15-8C52-8C4B67ABBAF5

P2860

Q34174334-01A00ACB-9D43-4711-92CA-5CF20E6381AC

Q34174334-020627F7-0530-4A1F-8D98-10ABD6A15032

Q34174334-05D2914E-49D7-4162-B525-8F7E2450D566

Q34174334-06949F68-845B-4E30-8CE2-38C19E27CD3D

Q34174334-0977538F-5C2B-455E-B1CC-C187C749EDC1

Q34174334-0EF88DE9-45B3-498C-B2D7-A0DAC26F20CC

Q34174334-16184CD9-33F1-417C-8671-8A38AC15681A

Q34174334-164A759F-FD92-4CA7-BB53-378364E4B969

Q34174334-1A6847F6-70C7-4108-8B2A-4B29D17821AA

Q34174334-20C2A303-2DFE-43E6-B278-4848EAF598B6

P304

Q34174334-E51711E5-8075-438B-AA02-FEE4B3370909

P31

Q34174334-B089C0B6-9D48-477E-B019-8814ABAB0F42

P356

Q34174334-D16EC8FD-C5A1-4461-A434-EB664A4091B8

P407

Q34174334-6B56A66C-9FC4-4DB5-B9C8-5CF124997C22

P433

Q34174334-206A3AB1-D4BB-4924-B19F-D89FDA167B1C

P478

Q34174334-1C3C9BBC-C9F3-42DF-974A-9B64D0BB5412

P50

Q34174334-19E9F7AB-BEE5-4A8C-ACB2-554D20AE1E4B

P577

Q34174334-71D3B786-5F54-4B9E-A308-04491DCA3DAA

P698

Q34174334-4A26D2C0-0C14-4C8C-87A4-4A1084231BC5

P921

Q34174334-0F3F70A7-F878-49CB-BE74-477B0D864C5B

Q34174334-C612369C-7DE1-436D-A3F4-7095C5BD1D15

P356

14712598.2011.572874

P1433

Expert Opinion on Biological Therapy

P1476

Bispecific antibodies engage T cells for antitumor immunotherapy.

@en

P2093

Ankit I Mehta

http://www.w3.org/2001/XMLSchema#string

Bryan D Choi

http://www.w3.org/2001/XMLSchema#string

Chien-Tsun Kuan

http://www.w3.org/2001/XMLSchema#string

John H Sampson

http://www.w3.org/2001/XMLSchema#string

Mingqing Cai

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

"Diabodies": small bivalent and bispecific antibody fragments

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

Continuous cultures of fused cells secreting antibody of predefined specificity

Cancer statistics, 2010

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

Bispecific T-cell engaging antibodies for cancer therapy

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

P304

843-853

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2011.572874

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Darell D. Bigner

P577

2011-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21449821

http://www.w3.org/2001/XMLSchema#string

P921